Market Closed -
Canadian Securities Exchange
12:55:04 11/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.025
CAD
|
0.00%
|
|
+25.00%
|
0.00%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
23.08
|
19.51
|
5.947
|
14.76
|
12.79
|
13.38
|
Enterprise Value (EV)
1 |
25.7
|
23.1
|
10.67
|
17.62
|
15.71
|
16.67
|
P/E ratio
|
-2.91
x
|
-1.34
x
|
-1.66
x
|
-3.6
x
|
-7.36
x
|
-8.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,038
x
|
1,263
x
|
1,962
x
|
-
|
-
|
-
|
EV / Revenue
|
1,156
x
|
1,495
x
|
3,519
x
|
-
|
-
|
-
|
EV / EBITDA
|
-5.81
x
|
-3.35
x
|
-3.13
x
|
-8.47
x
|
-18.9
x
|
-16.2
x
|
EV / FCF
|
-59.6
x
|
-70.8
x
|
-12.9
x
|
-1,140
x
|
-53.9
x
|
-67.8
x
|
FCF Yield
|
-1.68%
|
-1.41%
|
-7.77%
|
-0.09%
|
-1.86%
|
-1.48%
|
Price to Book
|
-67
x
|
-8.54
x
|
-1.33
x
|
-4.1
x
|
-3.12
x
|
-2.89
x
|
Nbr of stocks (in thousands)
|
2,45,523
|
3,90,189
|
3,96,449
|
4,92,149
|
5,11,703
|
5,35,303
|
Reference price
2 |
0.0940
|
0.0500
|
0.0150
|
0.0300
|
0.0250
|
0.0250
|
Announcement Date
|
24/04/18
|
18/04/19
|
29/04/20
|
13/04/21
|
02/05/22
|
01/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.0222
|
0.0155
|
0.003031
|
-
|
-
|
-
|
EBITDA
1 |
-4.425
|
-6.887
|
-3.408
|
-2.079
|
-0.8298
|
-1.026
|
EBIT
1 |
-4.442
|
-6.923
|
-3.436
|
-2.093
|
-0.8349
|
-1.036
|
Operating Margin
|
-19,978.8%
|
-44,802.96%
|
-1,13,356.09%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.329
|
-11.92
|
-3.587
|
-3.807
|
-1.747
|
-1.481
|
Net income
1 |
-7.232
|
-11.88
|
-3.579
|
-3.801
|
-1.727
|
-1.481
|
Net margin
|
-32,526.24%
|
-76,909.98%
|
-1,18,076.54%
|
-
|
-
|
-
|
EPS
2 |
-0.0323
|
-0.0373
|
-0.009043
|
-0.008341
|
-0.003399
|
-0.002839
|
Free Cash Flow
1 |
-0.4313
|
-0.3264
|
-0.8289
|
-0.0155
|
-0.2916
|
-0.246
|
FCF margin
|
-1,939.97%
|
-2,112.59%
|
-27,348.93%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/04/18
|
18/04/19
|
29/04/20
|
13/04/21
|
02/05/22
|
01/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
2.62
|
3.59
|
4.72
|
2.86
|
2.91
|
3.29
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.5929
x
|
-0.5209
x
|
-1.385
x
|
-1.374
x
|
-3.511
x
|
-3.203
x
|
Free Cash Flow
1 |
-0.43
|
-0.33
|
-0.83
|
-0.02
|
-0.29
|
-0.25
|
ROE (net income / shareholders' equity)
|
2,259%
|
904%
|
106%
|
94%
|
44.8%
|
33.9%
|
ROA (Net income/ Total Assets)
|
-198%
|
-192%
|
-156%
|
-226%
|
-225%
|
-370%
|
Assets
1 |
3.656
|
6.182
|
2.3
|
1.685
|
0.767
|
0.4008
|
Book Value Per Share
2 |
-0
|
-0.0100
|
-0.0100
|
-0.0100
|
-0.0100
|
-0.0100
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
1 |
0.17
|
0.01
|
-
|
-
|
-
|
-
|
Capex / Sales
|
746.93%
|
49.63%
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/04/18
|
18/04/19
|
29/04/20
|
13/04/21
|
02/05/22
|
01/05/23
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 9.8M | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|